Mylan Says Generic Drugs Can't Override IP Venue Law
The Hatch-Waxman Act didn't create an exemption to patent venue law that allows generic-drug makers to be sued in states where there's been no alleged infringement, Mylan has told the Federal...To view the full article, register now.
Already a subscriber? Click here to view full article